Влияние глюкозаминилмурамоилдипептида на биологическую активность цисплатина и фактора некроза опухолей-?
Диссертация
Суспензии клеток L-929 (1×105 клеток на лунку) в объеме 0,5 мл полной ростовой среды помещали в лунки 24-луночного плоскодонного планшета. Клетки инкубировали в СОг-инкубаторе в течение ночи, затем к ним добавляли препараты ГМДП и ФНОа в конечных концентрациях 10 мкг/мл и 500 ед./мл, соответственно. Объем жидкости в каждой лунке планшета доводился средой без ЭТС до 1 мл. Затем проводили инкубацию… Читать ещё >
Содержание
- СПИСОК СОКРАЩЕНИЙ
- ГЛАВА 1. ЛИТЕРАТУРНЫЙ ОБЗОР
- 1. 1. Программируемая клеточная гибель и фактор некроза опухолей
- 1. 1. 1. Пути реализации апоптоза
- 1. 1. 2. Виды клеточной гибели, отличные от апоптоза
- 1. 1. 3. ФНОа, история открытия, общая характеристика
- 1. 1. 4. Механизм действия ФНОа и его общие биологические эффекты
- 1. 1. 5. Механизм действия ФНОа на клетки L
- 1. 2. Мурамоилпептиды
- 1. 2. 1. Особенности химической структуры мурамоилпептидов
- 1. 2. 2. Биологическая активность мурамоилпептидов
- 1. 2. 3. Клетки-мишени мурамоилпептидов
- 1. 2. 4. Молекулярные механизмы биологического действия мурамоилпептидов
- 1. 2. 5. Использование мурамоилпептидов в противоопухолевой терапии
- 1. 2. 6. Совместные эффекты мурамоилпептидов с различными веществами
- 1. 1. Программируемая клеточная гибель и фактор некроза опухолей
Список литературы
- Ярилин А. Апоптоз: природа феномена и его роль в норме и при патологии, в кн. Актуальные проблемы патофизиологии, под ред. Б. Мороза. Медицина: Москва, 2001. С. 13−56.
- Самуилов В., Олескин А., Лагунова Е. Программируемая клеточная смерть. (2000) Биохимия. 65(8), 1029−1046.
- Kerr J., Wyllie A., Currie A. Apoptosis: a basic biological phenomenon with wideranging implications in tissue kinetics. (1972) Br J Cancer. 26(4), 239−257.
- Guimaraes C., Linden R. Programmed cell deaths. Apoptosis and alternative deathstyles. (2004) Eur J Biochem. 271(9), 1638−1650.
- Okada H., Mak T. Pathways of apoptotic and non-apoptotic death in tumour cells. (2004) Nat Rev Cancer. 4(8), 592−603.
- Барышников А., Шишкин Ю. Иммунологические проблемы апоптоза. Москва: Эдиториал УРСС, 2002. С. 11−14.
- Adams J. Ways of dying: multiple pathways to apoptosis. (2003) Genes Dev. 17(20), 2481−2495.
- Cohen G. Caspases: the executioners of apoptosis. (1997) Biochem J. 326(Pt 1), 1−16.
- Riedl S., Shi Y. Molecular mechanisms of caspase regulation during apoptosis. (2004) Nat Rev Mol Cell Biol. 5(11), 897−907.
- Ashkenazi A., Dixit V. Death receptors: signaling and modulatioa (1998) Science. 281(28), 1305−1308.
- Shu K., Li В., Wu L. The p53 network: p53 and its downstream genes. (2007) Colloids Surf В Biointerfaces. 55(1), 10−18.
- Lleo A., Invernizzi P., Selmi C., Coppel R., Alpini G., Podda M., Mackay I., Gershwin M. Autophagy: Highlighting a novel player in the autoimmunity scenario. (2007) J Autoimmunity. 29, 61−68.
- Han S., Kim Y.-S., Kim T.-H. Role of apoptotic and necrotic cell death under physiologic conditions. (2008) BMB Reports. 41(1), 1−10.
- Carswell E., Old L., Kassel R., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. (1975) Proc Natl Acad Sci USA. 72(9), 3666−3670.
- Ярилин А. Основы иммунологии. Москва: Медицина, 1999. С. 259−262.
- Kriegler M., Perezb С., DeFaya К., Alberta I., Lu S. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. (1988) Cell. 53(1), 45−53.
- Tang P., Hung M.-C., Klostergaard J. Human pro-tumor necrosis factor is a homotrimer. (1996) Biochemistry. 35(25), 8216−8225.
- Locksley R., Killeen N., Lenardo M. The TNF and TNF receptor superfamilies: integrating mammalian biology. (2001) Cell. 104(4), 487−501.
- Nagata S. Apoptosis by death factor. (1997) Cell. 88(3), 355−365.
- Wajant H., Pfizenmaier K., Scheurich P. Tumor necrosis factor signaling. (2003) Cell Death Differ. 10, 45−65.
- Hehlgans Т., Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. (2005) Immunology. 115, 120.
- Несмеянов В. (1997) Цитокины иммунной системы, в кн. Белки иммунной системы, под ред. В. Иванова. ИБХ РАН: Москва, 1997. С. 79−120.
- Ковальчук Л., Ганковская Л., Рубакова Э. Система цитокинов. РГМУ: Москва. 2000. С. 21−23.
- Earle W. Production of malignancy in vitro. IV. The mouse fibroblast cultures and changes seen in the living cells. (1943) J Natn Cancer Inst. 4, 165−212.
- Sanford K., Earle W., Likely G. The growth in vitro of single isolated tissue cells. (1948) J Natl Cancer Inst. 9(3), 229−246.
- Sugarman В., Aggarwal В., Hass P., Figari I., Jr M.P., Shepard H. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. (1985) Science. 230(4728), 943−945.
- Ruff M., Gifford G. Rabbit tumor necrosis factor: mechanism of actioa (1981) Infect Immun. 31(1), 380−385.
- Humphreys D., Wilson M. Modes of L929 cell death induced by TNF-alpha and other cytotoxic agents. (1999) Cytokine. 11(10), 773−782.
- Мошникова А., Кротова К., Галат В., Афанасьев В., Садовников В., Белецкий И. Апоптоз клеток L-929 под действием фактора некроза опухолей. (2000) Цитология. 42(6), 561−567.
- Lagarkova M., Iarovaia O., Razin S. Large-scale fragmentation of mammalian DNA in the course of apoptosis proceeds via excision of chomosomal DNA loops and their oligomers. (1995) J Biol Chem. 270(35), 20 239−20 241.
- Kouroku Y., Fujita E., Jimbo A., Mukasa T., Tsuru T., Momoi M., Momoi T. Localization of active form of caspase-8 in mouse L929 cells induced by TNF treatment and polyglutamine aggregates. (2000) Biochem Biophys Res Commun. 270(3), 972−977.
- Tafani M., Schneider T., Pastorino J., Farber J. Cytochrome c-dependent activation of caspase-3 by tumor necrosis factor requires induction of the mitochondrial permeability transition. (2000) Am J Pathol. 156(6), 2111−2121.
- Piret J., Arnould T., Fuks B., Chatelain P., Remacle J., Michiels C. Caspase activation precedes PTP opening in TNF-alpha-induced apoptosis in L929 cells. (2004) Mitochondrion. 3(5), 261−278.
- Hennet T., Richter C., Peterhans E. Tumour necrosis factor-alpha induces superoxide anion generation in mitochondria of L929 cells. (1993) Biochem J. 289(Pt2), 587−592.
- Powell C., Herzog T., Scott J., Collins J. Evidence for a protein synthesis-dependent and -independent TNF alpha cytolytic mechanism. (1995) Gynecol Oncol. 58(3), 327−335.
- Hehner S., Hofmann Т., Ratter F., Dumont A., Droge W., Schmitz M. Tumor necrosis factor-alpha-induced cell killing and activation of transcription factor NF-kappaB are uncoupled in L929 cells. (1998) J Biol Chem. 273(29), 18 117−18 121.
- Jayadev S., Hayter H., Andrieu N., Gamard C., Liu В., Balu R., Hayakawa M., Ito F., Hannun Y. Phospholipase A2 is necessary for tumor necrosis factor alpha-induced ceramide generation in L929 cells. (1997) J Biol Chem. 272(27), 17 169−17 203.
- Thon L., Mohlig H., Mathieu S., Lange A., Bulanova E., Winoto-Morbach S., Schutze S., Bulfone-Paus S., Adam D. Ceramide mediates caspase-independent programmed cell death. (2005) FASEB J. 19(14), 1945−1956.
- Strelow A., Bernardo K., Adam-Klages S., Linke Т., Sandhoff K., Kronke M., Adam D. Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death. (2000) J Exp Med. 5(4), 601−611.
- Lavelle E., McGuirk P., Mills K. Molecules of infectious agents as immunomodulatory drugs. (2004) Curr Top Med Chem. 2004(4), 5.
- Hamann L., El-Samalouti V., Ulmer A., Fiad H., Rietschel E. Components of gut bacteria as immunomodulators. (1998) Int J Food Microbiol. 41(2), 141−154.
- Гусев M., Минеева JI. Микробиология, 4-е изд. Москва: Издательский центр «Академия», 2003.
- Pabst М., Beranova-Giorgianni S., Krueger J. Effects of muramyl peptides on macrophages, monokines, and sleep. (1999) Neuroimmunomodulation. 6(4), 261−283.
- Andronova Т., Ivanov V. (1991) The structure and immunomodulating function of glucosaminylmuramyl peptides, in Sov Medical Review D Immunology. Harwood Academic Publishers, pp. 1−63.
- Adam A., Ciorbaru R., Petit J.-F., Lederer E. Isolation and properties of a macromolecular, water-soluble, immuno-adjuvant fraction from the cell wall of Mycobacterium smegmatis. (1972) Proc Natl Acad Sci USA. 69(4), 851−854.
- Ellouz F., Adam A., Ciorbaru R., Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. (1974) Biochem Biophys Res Commun. 59(4), 1317−1325.
- Kotani S., Watanabe Y., Kinoshita F., Shimono Т., Morisaki I. Immunoadjuvant activities of synthetic N-acetyl-muramyl-peptides or -amino acids. (1975) Biken J. 18(2), 105 111.
- Богданов И., Величков В., Гуревич А., Далев П., Колосов М. Антиопухолевые эффекты гликопептидов клеточной стенки Lactobacillus bulgaricus. (1977) Бюлллетень Экспериментальной Биологии и Медицины. 84(12), 709−712.
- Bogdanov I., Dalev P., Gurevich A., Kolosov M., Mal’kova V., Plemyannikova L., Sorokina I. Antitumour glycopeptides from Lactobacillus bulgaricus cell wall. (1975) FEBS Lett. 57(3), 259−261.
- Андронова Т., Ростовцева Л., Добрушкина Е., Гаврилов Ю., Дешко Т., Иванов В. О структуре противоопухолевого гликопептида из клеточной стенки Lactobacillus bulgaricus. (1980) Биоорганическая Химия. 6(12), 1830−1840.
- Ростовцева Л., Андронова Т., Малькова В., Сорокина И., Иванов В. Синтез и противоопухолевое действие гликопептидов, содержащих N-ацетилглюкозаминил-ф 1 -4)-N-ацетилмурамил-дисахаридное звено. (1981) Биоорганическая химия. 7(12), 1843−1858.
- Lefrancier P., Lederer E. Muramyl-peptides. (1987) Pure Appl Chem. 59(3), 449−454.
- Tandon P., Utsugi Т., Sone S. Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide. (1986) Cancer Res. 46(10), 5039−5044.
- Sone S., Mutsuura S., Ogawara M., Tsubura E. Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes. (1984) J Immunol. 132(4), 2105−2110.
- Akasaki M., Takashi T., Kita Y., Tsukada W. Augmentation of immune responses by a muramyl dipeptide analog, MDP-Lys (L18). (1987) Agents Actions. 22(1−2), 144−150.
- Karnovsky M.L. Muramyl peptides in mammalian tissues and their effects at the cellular level. (1986) Fed Proc. 45(11), 2556−2560.
- Johannsen L. Biological properties of bacterial peptidoglycan. (1993) APMIS. 101(5), 337−44.
- Shockman G., Daneo-Moore L., Kariyama R., Massidda. O. Bacterial walls, peptidoglycan hydrolases, autolysins, and autolysis. (1996) Microb Drug Resist. 2(1), 95−98.
- Vermeulen M., Gray G. Processing of Bacillus subtilis peptidoglycan by a mouse macrophage cell line. (1984) Infect Immun. 46(2), 476−483.
- Johannsen L., Wecke J., Jr F.O., Krueger J. Macrophages produce somnogenic and pyrogenic muramyl peptides during digestion of staphylococci. (1991) Am J Physiol Regul Integr Comp Physiol. 260(1), R126-R133.
- Fincher E., Johannsen L., Kapas L., Takahashi S., Krueger J. Microglia digest Staphylococcus aureus into low molecular weight biologically active compounds. (1996) Am J Physiol Regul Integr Comp Physiol. 271, 149 156.
- Khaitov R., Kulakov A., Pinegin В., Makarov E., Ledger P. The study of serum level and immunochemical properties of natural antibodies to N-acetylglucosaminyl-N-acetylmurarnyl dipeptide in healthy donors. (1996) Russ J Immunol. 1(1), 5−8.
- Иванов В., Андронова Т., Несмеянов В., Пинегин Б., Ledger P., Bomford R., Хаитов Р. Механизм действия и клиническая эффективность иммуномодулятора глюкозаминилмурамил дипептида (ликопида). (1997) Клиническая медицина. 3,11−15.
- Fox A., Fox К. Rapid elimination of a synthetic adjuvant peptide from the circulation after systemic administration and absence of detectable natural muramyl peptides in normal serum at current analytical limits. (1991) Ifect Immun. 59(3), 1202−1205.
- Harrison J., Fox A. Degradation of muramyl dipeptide by mammalian serum. (1985) Infect Immun. 50(1), 320−321.
- Ganley J., Redens Т., Kooragayala L., Welbourne Т., Langford M. Serum muramyl dipeptidase activity against synthetic bacterial cell wall peptidoglycans. (2003) Invest Ophthalmol Vis Sci. 44, E-abstract 1443.
- Fogler W., Wade R., Brundish D., Fidler I. Distribution and fate of free and liposome-encapsulated 3H. nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice. (1985) J Immunol. 135(2), 1372−1377.
- Shi F., Kurzman I., MacEwen E. In vitro and in vivo production of interleukin-6 induced by muramyl peptides and lipopolysaccharide in normal dogs. (1995) Cancer Biother. 10(4), 317−325.
- Adeleye Т., Moreno C., Ivanyi J., Aston R. The modulation of tumour necrosis factor-alpha, interleukin-1 alpha and glucose levels with GMDP and other analogues of muramyl dipeptide. (1994) APMIS. 102(2), 145−152.
- Fukuyama R., Takeda H., Fushiki S., Yamamoto T. Muramyl dipeptide injected into crushed sciatic nerve, activates macrophages and promotes recovery of walking locomotion in rats. (1998) Restor Neurol Neurosci. 13(3−4), 213−219.
- Sugawara Т., Takada S., Miyamoto M., Nomura M., Kato M. Inflammatory cytokine production induced by an analogue of muramyl dipeptide MDP-Lys (L18) in rat macrophage cultures and dog synovial fluid. (1996) Inflammation. 20(1), 43−56.
- Galelli A., Chariot В., Phillips N., Chedid L. Induction of colony-stimulating activity in mice by injection of liposomes containing lipophilic muramyl peptide derivatives. (1989) Cancer Res. 49(4), 810−815.
- Broudy V., Kaushansky K., Shoemaker S., Aggarwal В., Adamson J. Muramyl dipeptide induces production of hemopoietic growth factors in vivo by a mechanism independent of tumor necrosis factor. (1990) J Immunol. 144(10), 3789−3794.
- Tavares E., Maldonado R., Ojeda M., Minano F. Circulating inflammatory mediators during start of fever in differential diagnosis of gram-negative and gram-positive infections in leukopenic rats. (2005) Clin Diagn Lab Immunol. 12(9), 1085−1093.
- Пименов А., Рахмилевич А., Деев В., Кириллова И., Мигдаль Т., Андронова Т., Фукс В. Активация клеточного иммунитета у мышей в норме и при опухолевом росте под действием глюкозаминилмурамилдипептида (1990) Вопросы Медицинской Химии. 36(1), 58−60.
- Cummings N., Pabst M., Jr R.J. Activation of macrophages for enhanced release of superoxide anion and greater killing of Candida albicans by injection of muramyl dipeptide. (1980) J Exp Med. 152, 1659−1669.
- Fidler I., Sone S., Fogler W., Barnes Z. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. (1981) Proc Natl Acad Sci USA. 78(3), 1680−1684.
- Garrec Y.L., Morin A. Modulation of natural killer activity by muramyl peptides: relationship with adjuvant and anti-infectious properties. (1987) Nat Immun Cell Growth Regul. 6(2), 65−76.
- Talmadge J., Schneider M., Collins M., Phillips H., Herberman R., Wiltrout R. Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE. (1985) J Immunol. 135(2), 1477−1483.
- Chedid L., Audibert F., Lefrancier P., Choay J., Lederer E. Modulation of the immune response by a synthetic adjuvant and analogs. (1976) Proc Natl Acad Sci USA. 73(7), 24 722 475.
- Specter S., Cimprich R., Friedman H., Chedid L. Stimulation of an enhanced in vitro immune response by a synthetic adjuvant, muramyl dipeptide. (1978) J Immunol. 120(2), 487 491.
- Reese R., Trager W., Jensen J., Miller D., Tantravahi R. Immunization against malaria with antigen from Plasmodium falciparum cultivated in vitro. (1978) Proc Natl Acad Sci USA. 75(11), 5665−5668.
- Lowy I., Bona C., Chedid L. Target cells for the activity of a synthetic adjuvant: Muramyl dipeptide. (1977) Cell Immunol. 29(1), 195−199.
- Pietersz G., Li W., Popovski V., Caruana J., Apostolopoulos V., McKenzie I. Parameters for using mannan-MUCl fusion protein to induce cellular immunity. (1998) Cancer Immunol Immunother. 45(6), 321−326.
- Fast D., Vosika G. The muramyl dipeptide analog GMTP-N-DPG preferentially induces cellular immunity to soluble antigens. (1997) Vaccine. 15(16), 1748−1752.
- Vogel F., Powell M. A compendium of vaccine adjuvants and excipients. (1995) Pharm Biotechnol. 6, 141−228.
- Pap В., Макаров E., Юровский В., Мещерякова Е., Андронова Т., Иванов В. Синтетические иммуногенные комплексы на основе пептида поверхностного белка вируса ящура (1990) Биоорганическая Химия. 16(7), 904−915.
- Иванов В., Мещерякова Е., Андронова Т., Иванов В. Использование синтетических носителей и адъювантов для повышения иммуногенности синтетического пептида CS-белка Plasmodium falciparum. (1991) Биоорганическая Химия. 17(6), 732−746.
- Stills H. Adjuvants and antibody production: dispelling the myths associated with freund’s complete and other adjuvants. (2005) ILAR Journal. 46(3), 281−293.
- Passlick В., Labeta M., Izbicki J., Ostertag P., Loffler Т., Siebeck M., Pichlmeier U., Schweiberer L., Ziegler-Heitbrock H. Prevention of experimental endotoxin shock by a monocyte activator. (1995) Antimicrob Agents Chemother. 39(11), 2535−2540.
- Пинегин Б., Андронова Т., Карсонова М. Препараты мурамилдипептидного ряда иммунотропные лекарственные средства нового поколения. (1997) International Journal on Immunorehabilitation. 6(27−33).
- Azuma I. Development of the cytokine inducer romurtide: experimental studies and clinical applicatioa (1992) Trends Pharmacol Sci. 13(12), 425−428.
- Семенова И. Принципы коррекции вторичных иммунодефицитов путем использования двух иммуномодуляторов различной природы очищенного стафилококкового анатоксина и ликопида (1998) Журнал Микробиологии, Эпидемиологии и Иммунобиологии. 1,100−104. -
- Баранова И., Молотинов В., Симонова А. Клинико-иммунологическая эффективность применения иммуномодуляторов в лечении больных фурункулёзом. (1998) Иммунология. 4, 63−64.
- Свистунова А., Аршинова С., Климова С., Симонова А., Мазуров Д., Голубева Н., Андронова Т. Клиническая и иммунологическая эффективность иммуномодулятора ликопида при туберкулезе легких. (2000) Иммунология. 5, 59−62.
- Riveau G., Masek K., Parant M., Chedid L. Central pyrogenic activity of muramyl dipeptide. (1980) J Exp Med. 152(4), 869−877.
- Johannsen L., Obal F., Kapas L., Kovalzon V., Krueger J. Somnogenic activity of muramyl peptide-derived immune adjuvants. (1994) Int J Immunopharmacol. 16(2), 109−116.
- Lederer E. (1988) Natural and synthetic immunomodulators derived from the mycobacterial cell wall, in Advanses in Immunomodulation, B. Bizzini, E. Bonmassar, Editors. Pythagora Press: Roma-Milan, pp. 9−36.
- Balitsky K., Umansky V., Tarakhovsky A., Andronova T., Ivanov V. Glucosaminylmuramyl dipeptide-induced changes in murine macrophage metabolism. (1989) Int J Immunopharmacol. 11(5), 429−434.
- Darcissac E., Bahr G., Parant M., Chedid L., Riveau G. Selective induction, of CD1 la, b, c/CD18 and CD54 expression at the cell surface of human leukocytes by muramyl peptides. (1996) Cell Immunol. 169(2), 294−301.
- Nesmeyanov V., Khaidukov S., Komaleva R., Andronova T., Ivanov V. Muramylpeptides augment expression of la-antigens on mouse macrophages. (1990) Biomed Sci. 1(2), 151−154.
- Khaidukov S., Komaleva R., Nesmeyanov V. N-acetylglucosamine-containing muramyl peptides directly affect macrophages. (1995) Int J Immunopharmacol. 17(11), 903−911.
- Todd R., Alvarez P., Brott D., Liu D. Bacterial lipopolysaccharide, phorbol myristate acetate, and muramyl dipeptide stimulate the expression of a human monocyte surface antigen, Mo3e. (1985) J Immunol. 135(6), 3869−3877.
- Cohen L., Courtois G., Parant M. Differentiation of murine pre-B cell line by an adjuvant muramyl peptide viaNF-KB activation. (1995) Immunobiology. 193(5), 363−377.
- Todate A., Suda T., Kuwata H., Chida K., Nakamura H. Muramyl dipeptide-Lys stimulates the function of human dendritic cells. (2001) J Leukoc Biol. 70(5), 273−279.
- Riveau G., Brunel-Riveau В., Audibert F., Chedid L. Influence of a muramyl dipeptide on human blood leukocyte functions and their membrane antigens. (1991) Cell Immunol. 134(1), 147−156.
- Валякина Т., Макаров E., Малахов А., Андронова Т., Ревазова Е., Несмеянов В., Иванов В. Мурамилпептиды повышают экспрессию опухолеассоциированных антигенов. (1993) Иммунология. 4, 32−36.
- Valyakina Т., Komaleva R., Petrova Е., Malakhov A., Shamborant О., Andronova Т., Nesmeyanov V. Endogenous tumour necrosis factor-alpha sensitise melanoma cells to glucosaminylmuramyl dipeptide. (1998) FEBS Lett. 426(3), 373−376.
- Langford М., Chen D., Welboume Т., Redens Т., Ganley J. Stereo-isomer specific induction of renal cell apoptosis by synthetic muramyl dipeptide (N-acetylmuramyl-:L-alanyl-D-isoglutamine). (2002) Mol Cell Biochem. 236(1−2), 63−73.
- Srur L., Langford M. Caspase mediated apoptosis of conjunctival cells associated with muramyl dipeptide induced conjunctivitis. (2007) Inves Ophtalmol Vis Sci. 48, E-abstract 1925.
- Galelli A., Dosne A., Morin A., Dubor F., Chedid L. Stimulation of human endothelial cells by synthetic muramyl peptides: production of colony-stimulating activity (CSA). (1985) Exp Hematol. 13(11), 1157−1163.
- Li C., Kumar S., Ledger P., Ponting J., Carette M., Allan E. Glucosaminylmuramyl dipeptide (GMDP) modulates endothelial cell activities in vitro but has no effect on angiogenesis in vivo. (1997) Inflamm Res. 46(9), 348−353.
- Silverman D., Wu H., Karnovsky M. Muramyl peptides and serotonin interact at specific binding sites on macrophages and enhance superoxide release. (1985) Biochem Biophys Res Commun. 131(3), 1160−1167.
- Polanski M., Karnovsky M. Serotonergic aspects of the response of human platelets to immune-adjuvant muramyl dipeptide. (1992) J Neuroimmunol. 37(1−2), 149−160.
- Polanski M., Vermeulen M., Wu J., Karnovsky M. Muramyl dipeptide mimicry in the regulation of murine macrophage activation by serotonin (1995) Int J Immunopharmacol. 17(3), 225−232.
- Silverman D., Krueger J., Karnovsky M. Specific binding sites for muramyl peptides on murine macrophages. (1986) J Immunol. 136(6), 2195−2201.
- Root-Bernstein R., Westall F. Serotonin binding sites. II. Muramyl dipeptide binds to serotonin binding sites on myelin basic protein, LHRH, and MSH-ACTH 4−10. (1990) Brain Res Bull. 25(6), 827−841.
- Мещерякова E., Алексеева JI. Поиск гликопептид- и серотонин-связывающих пептидов из рецептора серотонииа. (1996) Информационный Бюллетень РФФИ. 4(3), 314.
- Мещерякова Е. Поиск гликопептид- и серотонин-связывающих пептидов из рецептора серотонина (1998) Информационный Бюллетень РФФИ. 5(3), 237.
- Kaydalov A., Utkin Y., Andronova Т., Tsetlin V., Ivanov V. Muramyl peptides bind specifically to rat brain membranes. (1989) FEBS Lett. 248(1−2), 78−82.
- Кайдалов А., Уткин Ю., Андронова Т., Цетлин В., Иванов В. Специфическое связывание мурамоилпептидов с мембранами мозга крысы. (1987) Биоорганическая Химия. 13(11), 1523−1529.
- Tenu J., Adam A., Souvannavong V., Yapo A., Petit J., Douglas K. Photoafflnity• 1″) ^ labeling of macrophages and B-lymphocytes using I-labeled aryl-azide derivatives ofmuramyldipeptide. (1989) Int J Immunopharmacol. 11(6), 653−661.
- Sumaroka M., Litvinov I., Khaidukov S., Golovina Т., Kamraz M., Komaleva R., Andronova Т., Makarov E., Nesmeyanov V., et al. Muramyl peptide-binding sites are located inside target cells. (1991) FEBS Lett. 295(1−3), 48−50.
- Golovina Т., Sumaroka M., Samokhvalova L., Shebzukhov Y., Andronova Т., Nesmeyanov V. Biochemical characterization of glucosaminylmuramyldipeptide binding sites of murine macrophages. (1994) FEBS Lett. 365, 9−12.
- Головина Т., Сумарока M., Самохвалова Л., Шебзухов Ю., Макаров Е., Несмеянов В. Полипептиды из мышиных перитонеальных макрофагов, распознающие глюкозаминилмурамоилдипептид. (1995) Биоорганическая Химия. 21(4), 268−274.
- Golovina Т., Fattakhovaa G., Swiderekb К., Makarov Е., Bovina N., Shivelyb J., Nesmeyanov V. Specific binding of glucosaminylmuramyl peptides to histones. (1999) FEBS Lett. 454,152−156.
- Ohe Y., Hayashi H., Iwai K. Human spleen histone HI. Isolation and amino acid sequence of a main variant, Hlb. (1986) J Biochem (Tokyo). 100(2), 359−368.
- Dziarski R. Recognition of bacterial peptidoglycan by the innate immune system. (2003) Cell Mol Life Sci. 60, 1793−1804.
- Chen D., Texada D., Duggan C., Liang C., Reden Т., Kooragayala L., Langford M. Surface calreticulin mediates muramyl dipeptide-induced apoptosis in RK13 cells. (2005) J Biol Chem. 280(23), 22 425−2236.
- Dziarski R., Tapping R., Tobias P. Binding of bacterial peptidoglycan to CD 14. (1998) J Biol Chem. 273(15), 8680−8690.
- Inamura S., Fujimoto Y., Kawasaki A., Shiokawa Z., Woelk E., Heine H., Lindner В., Inohara N., Kusumotoa S., et al. Synthesis of peptidoglycan fragments and evaluation of their biological activity. (2006) Org Biomol Chem. 4, 232−242.
- Girardin S., Boneca I., Viala J., Chamaillard M., Labigne A., Thomas G., Philpott D., Sansonetti P. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detectioa (2003) J Biol Chem. 278(11), 8869−8872.
- Chamaillard M., Hashimoto M., Horie Y., Masumoto J., Qiu S., Saab L., Ogura Y., Kawasaki A., Fukase K., et al. An essential role for NODI in host recognition of bacterial peptidoglycan containing diaminopimelic acid. (2003) Nat Immunol. 4(7), 702−707.
- Pauleau A.-L., Murray P. Role of Nod2 in the response of macrophages to toll-like receptor agonists. (2003) Mol Cell Biol. 23(21), 7531−7539.
- Kobayashi K., Chamaillard M., Ogura Y., Henegariu O., Inohara N., Nunez G., Flavell R. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. (2005) Science. 307(4), 731−734.
- Girardin S., Travassos L., Herve M., Blanot D., Boneca I., Philpott D., Sansonetti P., Mengin-Lecreulx D. Peptidoglycan molecular requirements allowing detection by Nodi and Nod2. (2003) J Biol Chem. 278(43), 41 702−41 708.
- Inohara N., Nunez G. NODS: intracellular proteins involved in inflammation and apoptosis. (2003) Nat Rew Immunol. 3, 371−382.
- Tanabe T., Chamaillard M., Ogura Y., Zhu L., Qiu S., Masumoto J., Ghosh P., Moran A., Predergast M., et al. Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognitioa (2004) EMBO J. 23(7), 1587−1597.
- Leung E., Honga J., Fraser A., Krissansen G. Splicing of NOD2 (CARD 15) RNA transcripts. (2007) Moll Immunol. 44, 284−294.
- Murray P. NOD proteins: an intracellular pathogen-recognition system or signal transduction modifiers? (2005) Curr Opin Immunol. 17, 352−358.
- Windheim M., Lang C., Peggie M., Plater L., Cohen P. Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide. (2007) Biochem J. 404(2), 179−190.
- Yang Y., Yin C., Pandey A., Abbott D., Sassetti C., Kelliher M. NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2. (2007) J Biol Chem. 282(50), 36 223−36 229.
- Kim J.-Y., Omori E., Matsumoto K., Nunez G., Ninomiya-Tsuji J. TAK1 is a central mediator of NOD2 signaling in epidermal cells. (2007) J Biol Chem. 283(1), 137−144.
- Pan Q., Kravchenko V., Katz A., Huang S., Ii M., Mathison J., Kobayashi K., Flavell R., Schreiber R., et al. NF-KB-Inducing Kinase Regulates Selected Gene Expressionin the Nod2 Signaling Pathway. (2006) Infect Immun. 74(4), 2121−2127.
- Kufer T., Kremmer E., Banks D., Philpott D. Role for erbin in bacterial activation of Nod2. (2006) Infect Immun. 74(6), 3115−3124.
- McDonald C., Chen F., Ollendorff V., Ogura Y., Marchetto S., Lecine P., Borg J.-P., Nunez G. A role for erbin in the regulation of Nod2-dependent NF-kB signaling. (2005) J Biol Chem. 280(48), 40 301−40 309.
- Yamamoto-Furusho J., Barnich N., Xavier R., Hisamatsu T., Podolsky D. Centaurin pi down-regulates nucleotide-binding oligomerization domains 1- and 2-dependent NF-kB activation. (2006) J Biol Chem. 281(47), 36 060−36 070.
- Barnich N., Aguirre J., Reinecker H.-C., Xavier R., Podolsky D. Membrane recruitment of NOD2 in intestinal epithelial cells is essential for nuclear factor-kb activation in muramyl dipeptide recognition. (2005) J Cell Biol. 170(1), 21−26.
- Lecine P., Esmiol S., Metais J.-Y., Nicoletti C., Nourry C., McDonald C., Nunez G., Hugot J.-P., Borg J.-P., et al. The NOD2-RICK complex signals from the plasma membrane. (2007) J Biol Chem. 282(20), 15 197−15 207.
- Oh H., Lee H., Seo G., Choi E., Kweon S., Chun C., Han W., Lee K., Lee M., et al. Induction and localization of NOD2 protein in human endothelial cells. (2005) Cell Immunol. 237(1), 37−44.
- Hisamatsu T., Suzuki M., Reinecker H., Nadeau W., McCormick B., Podolsky D. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. (2003) Gastroenterology. 124(4), 993−1000.
- Ogura Y., Inohara N., Benito A., Chen F., Yamaoka S., Nunez G. Nod2, a Nodl/Apaf-1 family member that is restricted to monocytes and activates NF-kB. (2001) J Biol Chem. 276(7), 4812−4818.
- Gutierrez O., Pipaon K., Inohara N., Fontalba A., Ogura Y., Prosper F., Nunez G., Fernandez-Luna J. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kB activation (2002) J Biol Chem. 277(44), 41 701−41 705.
- D Sterka J., Marriott I. Characterization of nucleotide-binding oligomerization domain (NOD) protein expression in primary murine microglia (2006) J Neuroimmunol. 179(1−2), 6575.
- Costello M., Joyce S., Abrahams V. NOD protein expression and function in first trimester trophoblast cells. (2007) Am J Reprod Immunol. 57, 67−80.
- Davey M., Martin T., Planck S., Lee J., Zamora D., Rosenbaum J. Human endothelial cells express NOD2/CARD15 and increase IL-6 secretion in response to muramyl dipeptide. (2006) Microvasc Res. 71(2), 103−107.
- Rosenstiel P., Fantini M., Brautigam K., Kuhbacher T., Waetzig G., Seegert D., Schreiber S. TNF-a and IFN-y regulate the expression of the NOD2 (CARD 15) gene in human intestinal epithelial cells. (2003) Gastroenterology. 124(4), 1001−1009.
- Li J., Moran T., Swanson E., Julian C., Harris J., Bonen D., Hedl M., Nicolae D., Abraham C., et al. Regulation of IL-8 and IL-ip expression in Crohn’s disease associated NOD2/CARD15 mutations. (2004) Hum Mol Genet. 13(16), 1715−1725.
- Voss E., Wehkamp J., Wehkamp K., Stange E., Schroder J., Harder J. NOD2/CARD15 mediates induction of the antimicrobial peptide human p-defensin-2. (2006) J Biol Chem. 281(4), 2005−2011.
- Rosenzweig H., Davey M., Planck S., Sawkar H., Pengshung M., Jensen J., Goodwin K., Rosenbaum J.T., Martin T.M. Characterization of a novel model of NOD2-dependent ocular inflammatioa (2007) Invest Ophthalmol Vis Sci. 48, E-abstract 3628.
- Weichart D., Gobom J., Klopfleisch S., Hasler R., Gustavsson N., Billmann S., Lehrach H., Seegert D., Schreiber S., et al. Analysis of NOD2-mediated proteome response to muramyl dipeptide in HEK293 cells. (2006) J Biol Chem. 281(4), 2380−2389.
- Chamaillard M., Girardin S., Viala J., Philpott D. Nods, Nalps and Naip: intracellular regulators of bacterial-induced inflammatioa (2003) Cell Microbiol. 5(9), 581−592.
- Martinon F., Agostini L., Meylan E., Tschopp J. Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. (2004) Curr Biol. 14(9), 19 291 934.
- Faustin B., Lartigue L., Bruey J., Luciano F., Sergienko E., Bailly-Maitre B., Volkmann N., Hanein D., Rouiller I., et al. Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. (2007) Mol Cell. 25(5), 713−724. i
- Pan Q., Mathison J., Fearns C., Kravchenko V., Correia J., Hoffman H., Kobayashi K., Bertin J., Grant E., et al. MDP-induced interleukin-ip processing requires Nod2 and CIAS1/NALP3. (2007) J Leukoc Biol. 82(1), 177−183.
- Dong W., Liu Y., Peng J., Chen L., Zou T., Xiao H., Liu Z., Li W., Bu Y., et al. The IRAK-1 -BCL10-MALT1-TRAF6-TAK1 cascade mediates signaling to NF-B from toll-like receptor 4. (2006) J Biol Chem. 281(36), 26 029−26 040.
- Lenz L., Mohammadi S., Geissler A., Portnoy D. SecA2-dependent secretion of autolytic enzymes promotes Listeria monocytogenes pathogenesis. (2003) Proc Natl Acad Sci U S A. 100(21), 12 432−12 437.
- Chen D., Duggan C., Reden T., Kooragayala L., Texada D., Langford M. Calreticulin is a binding protein for muramyl dipeptide for muramyl dipeptide and peptidoglycan in RK13 cells. (2004) Biochemistry. 43, 11 796−11 801.
- Michalak M., Mesaeli E.C.N., Nakamura К., Opas M. Calreticulin: one protein, one gene, many functions. (1999) Biochem J. 344(2), 281−292.
- Groenendyk J., Lynch J., Michalak M. Calreticulin, Ca2+, and calcineurin signaling from the endoplasmic reticulum. (2004) Mol Cells. 17(3), 383−389.
- Elliott Т., Williams A. The optimization of peptide cargo bound to MHC class I molecules by the peptide-loading complex. (2005) Immunol Rev. 207, 89−99.
- Brownbill A., Braun D., Dukor P., Schumann G. Induction of tumouricidal leucocytes by the intranasal application of MTP-PE, a lipophilic muramyl peptide. (1985) Cancer Immunol Immunother. 20(1), 11 -17.
- Jarowenko D., Sigler S., Pellis N. Muramyl tripeptide: an effective immunotherapy in the surgical setting for pediatric abdominal neoplasms. (1987) J Pediatr Surg. 22(6), 497−500.
- Malik S., Martin D., Hart I., Balkwill F. Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF. (1991) Br J Cancer. 63(3), 399−403.
- Уманский В., Стефанов А., Бондарь О., Балицкий К., Пинчук В. Антиметастатический эффект заключенного в липосомы аналога мурамоилпептида. (1988) Вопросы Онкологии. 34(4), 433−438.
- Phillips N., Tsao M. Inhibition of experimental liver tumor growth in mice by liposomes containing a lipophilic muramyl dipeptide derivative. (1989) Cancer Res. 49(4), 936 939.
- Nitta Y., Sugita Т., Ikuta Y., Murakami T. Inhibitory effect of liposomal MDP-Lys on lung metastasis of transplantable osteosarcoma in hamster. (2000) Oncol Res. 12(1), 25−31.
- Yoo Y., Saiki I., Sato K., Azuma I. MDP-Lys (L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice. (1994) Vaccine. 12(2), 175−160.
- Nardin A., Lefebvre M.-L., Labroquere K., Faure O., Abastado J.-P. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma (2006) Curr Cancer Drug Targets. 6(2), 123−133.
- Talmadge J., Lenz B., Klabansky R., Simon R., Riggs C., Guo S., Oldham R., Fidler I. Therapy of autochthonous skin cancers in mice with intravenously injected liposomes containing muramyltripeptide. (1986) Cancer Res. 46(3), 1160−1163.
- Karpoff H., Jarnagin W., Delman K., Fong Y. Regional muramyl tripeptide phosphatidylethanolamine administration enhances hepatic immune function and tumor surveillance. (2000) Surgery. 128(2), 213−218.
- Thomas K., Nijenhuis A., Dontje B., Daernen T., Scherphof G. Antitumor reactivity induced by liposomal MTP-PE in a liver metastasis model of colon cancer in the rat. (1995) Clin Exp Metastasis. 13(5), 328−336.
- Dinney C., Tanguay S., Bucana C., Eve B., Fidler I. Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice. (1995) J Interferon Cytokine Res. 15(6), 585−592.
- Murray J., Kleinerman E., Cunningham J., Tatom J., Andrejcio K., Lepe-Zuniga J., Lamki L., Rosenblum M., Frost H., et al. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. (1989) J Clin Oncol. 7(12), 1915−1925.
- Urba W., Hartmann L., Longo D., Steis R., II J.S., Kedar I., Creekmore S., Sznol M., Gonion K., et al. Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine. (1990) Cancer Res. 50(10), 2979−2986.
- Gianan M., Kleinerman E. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update. (1998) Cancer Biother Radiopharm. 13(5), 363−368.
- Kleinerman E., Gano J., Johnston D., Benjamin R., Jaffe N. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma (1995) Am J Clin Oncol. 18(2), 93−99.
- Ullrich S., Fidler I. Liposomes containing muramyl. tripeptide phosphatidylethanolamine (MTP-PE) are excellent adjuvants for induction of ah immune response to protein and tumor antigens. (1992) J Leukoc Biol. 52(5), 489−494.
- Yoo Y., Saiki I., Sato K., Azuma I. B30-MDP, a synthetic muramyl" dipeptide derivative for tumour vaccination to enhance antitumour immunity and antimetastatic effect in mice. (1992) Vaccine. 10(11), 792−797.
- Asao T., Shibata H., Batist G., Brodt P. Eradication of hepatic metastases of carcinoma H-59 by combination chemoimmunotherapy with liposomal muramyl tripeptide, 5-fluorouracil, and leucovoria (1992) Cancer Res. 52(22), 6254−6257.
- Lowy I., Leclerc C., Bourgeois E., Chedid L. Inhibition of mitogen-induced polyclonal activation by by a synthetic adjuvant, muramyl dipeptide (MDP). (1980) J Immunol. 124(1), 320−325.
- Traub S., Aulock S.v., Hartung T., Hermann C. MDP and other muropeptides-direct and synergistic effects on the immune system. (2006) J Endotox Res. 12(2), 69−85.
- Galelli A., Chedid L. Induction of colony-stimulating activity (CSA) by a synthetic muramyl peptide (MDP): synergism with LPS and activity in C3H/HeJ mice and in endotoxin-tolerized mice. (1986) J Immunol. 137(10), 3211−3215.
- Parant M., Parant F., Vinit M., Jupin C., Noso Y., Chedid L. Priming effect of muramyl peptides for induction by lipopolysaccharide of tumor necrosis factor production in mice. (1990) J Leukoc Biol. 47(2), 164−169.
- Parant M., Pouillart P., Contel C.L., Parant F., Chedid L., Bahr G. Selective modulation of lipopolysaccharide-induced death and cytokine production by various muramyl peptides. (1995) Infect Immun. 63(1), 110−115.
- Meshcheryakova E., Guryanova S., Makarov E., Alekseeva L., Andronova T., Ivanov V. Prevention of experimental septic shock by pretreatment of mice with muramyl peptides. (2001) Int Immunopharmacol. 1(9−10), 1857−1865.
- Langhans W., Balkowski G., Savoldelli D. Differential feeding responses to bacterial lipopolysaccharide and muramyl dipeptide. (1991) Am J Physiol Regul Integr Conip Physiol. 261(3), R659-R664.
- Roth J., Asian T., Storr B., Zeisberger. E. Lack of cross tolerance between LPS and muramyl dipeptide in induction of circulating TNF-a and IL-6 in guinea pigs. (1997) Am J Physiol Regul Integr Comp Physiol. 273(4 Pt 2), R1529-R1533.
- Wolfert M., Murray T., Boons G.-J., Moore J. The origin of the synergistic effect of muramyl dipeptide with endotoxin and peptidoglycaa (2002) J Biol Chem. 277(42), 3 917 939 186.
- Traub S., Kubasch N., Morath S., Kresse M., Hartung T., Schmidt R., Hermann C. Structural requirements of synthetic muropeptides to synergize with lipopolysaccharide in cytokine inductioa (2004) J Biol Chem. 279(10), 8694−8700.
- Kim H., Yang J., Woo S., Kim S., Yun C.-H., Kim K., Han S. Lipoteichoic acid and muramyl dipeptide synergistically induce maturation of human dendritic cells and concurrent expression of proinflammatory cytokines. (2007) J Leukoc Biol. 81, 983−989.
- Slesarev V., Ellithorpe R., Dimitroff T. Inhibition of systemic TNF-a cytotoxicity in cancer patients by D-peptidoglycaa (1998) Med Oncol. 15(1), 73−43.
- Dubois С., Bissonnette E., Rola-Pleszczynski M. Platelet-activating factor (PAF) enhances tumor necrosis factor production by alveolar macrophages. Prevention by PAF receptor antagonists and lipoxygenase inhibitors. (1989) J Immunol. 143(3), 964−970.
- Salem P., Deryckx S., Dulioust A., Vivier E., Denizot Y., Damais C., Dinarello C., Thomas Y. Immunoregulatory functions of paf-acether. IV. Enhancement of IL-1 production by muramyl dipeptide-stimulated monocytes. (1990) J Immunol. 144(4), 1338−1344.
- Szlosarek P., Balkwill F. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. (2003) Lancet Oncol. 4(9), 565−573.
- Yao X., Panichpisal K., Kurtzman N., Nugent K. Cisplatin nephrotoxicity: a review. (2007) Am J Med Sci. 334(2), 115−124.
- Sacchi A., Gasparri A., Gallo-Stampino C., Toma S., Curnis F., Corti A. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha (2006) Clin Cancer Res. 12(1), 175−182.
- Петрова E. Изучение функциональной активности глюкозаминил-мурамоилдиггептида на опухолевых клетках. Автореферат дисс. на соискание уч. степени канд. биол. наук, Москва, 2002.
- Terlikowski S., Sulkowska М., Nowak Н. The effect of recombinant human tumor necrosis factor-alpha on Ehrlich ascites tumor growth. (2002) J Environ Pathol Toxicol Oncol. 21(1), 87−92.
- Трещалина E., Жукова О., Герасимова Г., Гарин А., Смирнова А. Методические рекомендации по изучению противоопухолевой активности фармакологических веществ, 1992, С. 319−325.
- Sosnowska D., Mysliwski A., Dzierzbicka K., Kolodziejczyk A. The in vitro effect of new muramyl peptide derivatives on cytotoxic activity of NK (natural killer) cells from hamsters bearing Ab Bomirski melanoma (1997) Biotherapy. 10(2), 161−168.
- Warzocha K., Robak T. Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice. (1992) Acta Haematol Pol. 23(1), 55−62.
- Maranda E., Robak T. Interactions of 2', 2'-diflurodeoxycytidine (gemcitabine) with tumor necrosis factor alpha or its mutein VI in murine leukemias L1210 and P388. (1998) Arch Immunol Ther Exp (Warsz). 46(2), 113−119.
- Wang D., Lippard S. Cellular processing of platinum anticancer drugs. (2005) Nat Rev Drug Duscovery. 4, 307−320.
- Арзамасцев E.B., Гуськова T.A., Либерман C.C., Любимов Б. И., Рудаков А. Г., Верстакова О. Л. Методические рекомендации по изучению общетоксического действия фармакологических средств, 1997.
- Aston R., Kovalev I. Muramyl peptide for the treatment of toxicity. Vol. PCT/GB93/408. USA: Peptech (UK) Limited (London, GB), 2003.
- Correia J.d.S., Miranda Y., Austin-Brown N., Hsu J., Mathison J., Xiang R., Zhou H., Li Q., Han J., et al. Nodi-dependent control of tumor growth. (2006) Proc Natl Acad Sci USA. 103(6), 1840−1845.
- Vermes I., Haanen C., Reutelingsperger C. Flow cytometry of apoptotic cell death. (2000) J Immunol Methods. 243(1−2), 167−190.
- Meers P., Mealy T. Calcium-dependent annexin V binding to phospholipids: stoichiometry, specificity, and the role of negative charge. (1993) Biochemistry. 32(43), 1 171 111 721.
- Rubin В., Anderson S., Sullivan S., Williamson В., Carswell E., Old L. Nonhematopoietic cells selected for resistance to tumor necrosis factor produce tumor necrosis factor. (1986) J Exp Med. 164(4), 1350−1355.
- Ченцов Ю. Введение в клеточную биологию, 4-е изд. Москва: Академкнига, 2004. С. 117−121.
- Lever М., Th’ng J., Sun X., Hendzel M. Rapid exchange of histone Hl. l on chromatin in living human cells. (2000) Nature. 408, 873−876.
- Bustin M., Catez F., Lim J.-H. The dynamics of histone HI function in chromatia (2005) Mol Cell. 17, 617−620.
- Woodcock C., Skoultchi A., Fan Y. Role of linker histone in chromatin structure and function: HI stoichiometry and nucleosome repeat length. (2006) Chromosome Res. 14(1), 1725.
- Головина Т. Локализация и характеристика мурамилпептидсвязывающих молекул клеток иммуной системы. Автореферат дисс. на соискание уч. степени канд. биол. наук, Москва, 1996.
- Johnson L., Walsh M., Chen L. Localization of mitochondria in living cells with rhodamine 123. (1980) Proc Natl Acad Sci USA. 77(2), 990−994.
- Faulkner K., Fridovich I. Luminol and lucigenin as detectors for O2″. (1993) Free Radic Biol Med. 15(4), 447−451.
- Самуилов В., Олескин А. Технологическая биоэнергетика. Москва: Издательство Московского университета, 1994. С. 44.
- Grivennikova V., Vinogradov A. Generation of superoxide by the mitochondrial Complex I. (2006) Biochim Biophys Acta. 1757(5−6), 553−561.
- National Drug Information Service. NDIS Profile on Cisplatin. Commonwealth Department of Human Services and Health, Canberra. 1985.
- Гулак П., Дудченко А., Зайцев В., Лукьянова Л., Новиков К., Орлов С., Покудин Н., Попова О., Уголев А. Гепатоцит: функционально-метаболические свойства. Москва: Наука, 1985. С. 125−145.
- Kaplan Е., Meier P. Non-parametric estimation from incomplete observations. (1958) J Am Stat Assoc 53,457−481.
- Mosmann Т. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. (1983) J Immunol Methods. 65(1−2), 55−63.
- Bustin M., Catez F., Lim J.-H. The dynamics of histone HI function in chromatia (2005) Mol Cell. 17,617−620.
- Woodcock C., Skoultchi A., Fan Y. Role of linker histone in chromatin structure and function: HI stoichiometry and nucleosome repeat length. (2006) Chromosome Res. 14(1), 1725.
- Головина Т. Локализация и характеристика мурамилпептидсвязывающих молекул клеток иммуной системы. Автореферат дисс. на соискание уч. степени канд. биол. наук, Москва, 1996.
- Johnson L., Walsh M., Chen L. Localization of mitochondria in living cells with rhodamine 123. (1980) Proc Natl Acad Sci USA. 77(2), 990−994.• • «J
- Faulkner K., Fridovich I. Luminol and lucigenin as detectors for О (1993) Free Radic Biol Med. 15(4), 447−451.
- Самуилов В., Олескин А. Технологическая биоэнергетика. Москва: Издательство Московского университета, 1994. С. 44.
- Grivennikova V., Vinogradov A. Generation of superoxide by the mitochondrial Complex I. (2006) Biochim Biophys Acta. 1757(5−6), 553−561.
- National Drug Information Service. NDIS Profile on Cisplatin. Commonwealth Department of Human Services and Health, Canberra. 1985.
- Гулак П., Дудченко А., Зайцев В., Лукьянова Л., Новиков К., Орлов С., Покудин Н., Попова О., Уголев А. Гепатоцит: функционально-метаболические свойства. Москва: Наука, 1985. С. 125−145.
- Kaplan Е., Meier P. Non-parametric estimation from incomplete observations. (1958) J Am Stat Assoc 53,457−481.
- Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. (1983) J Immunol Methods. 65(1−2), 55−63.